Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-IT101 in Advanced Renal Cancer
NCT07770802Phase 1Recruiting
- Sponsor
- Huasai Biomedicine
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-IT101 in clear cell renal cell carcinoma (ccRCC), sponsored by Huasai Biomedicine. Primary endpoint: Incidence and Severity of Adverse Events and Serious Adverse Events at 2 years. Started Aug 2026; status: recruiting.
02
Drugs
HS-IT101
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07770802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770802.